Anti-atherosclerotic potential of dihydropyridine calcium channel blockers

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 8, 2012, Pages 693-704

  Ishii, Norio ^a   Matsumura, Takeshi ^a   Shimoda, Seiya ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Dihydropyridine calcium channel blocker; Hypertension

Indexed keywords

AMLODIPINE; AZELNIDIPINE; BENIDIPINE; CHEMOKINE; CHOLESTEROL; CYTOKINE; DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER; DIHYDROPYRIDINE DERIVATIVE; LACIDIPINE; MATRIX METALLOPROTEINASE; NICARDIPINE; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; DRUG MECHANISM; ENDOTHELIUM CELL; ESTERIFICATION; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOGENESIS; REVIEW; SMOOTH MUSCLE FIBER;

EID: 84865706476     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.12450     Document Type: Review

References (128)

1. Peeters A, Mamun AA, Willekens F, Bonneux L: A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J, 2002; 23: 458-466
2. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
3. Libby P: Molecular bases of the acute coronary syndromes. Circulation, 1995; 91: 2844-2850
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). New Engl J Med, 1992; 326: 310-318
5. Henry PD: Atherosclerosis, calcium, and calcium antagonists. Circulation, 1985; 72: 456-459
6. The ENCORE Investigators: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation, 2003; 107: 422-428
7. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 2006; 113: 1213-1225
8. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 2000; 102: 1503-1510
9. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P; European Lacidipine Study on Atherosclerosis investigators: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation, 2002; 106: 2422-2427
10. Zhang X, Hintze TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mech-anism of action of a calcium channel-blocking agent. Circulation, 1998; 97: 576-580
11. Stepien O, Gogusev J, Zhu DL, Iouzalen L, Herembert T, Drueke TB, Marche P: Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol, 1998; 31: 786-793
12. Hernandez RH, Armas-Hernandez MJ, Velasco M, et al. Israili ZH, Armas-Padilla MC: Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther, 2003; 10: 409-414
13. Waters D, Lespérance J, Francetich M, Causey D, Théroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ: A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation, 1990; 82: 1940-1953
14. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet, 1990; 335: 1109-1113
15. Motro M, Shemesh J: Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension, 2001; 37: 1410-1413
16. Simon A, Gariepy J, Moyse D, Levenson J: Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation, 2001; 103: 2949-2954
17. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM; INSIGHT: Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 2003; 41: 431-436
18. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda A, Kawai C: Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Randomized Trial. Hypertens Res, 2004; 27: 181-191
19. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 2000; 102: 1503-1510
20. Brener SJ, Ivanc TB, Poliszczuk R, Chen M, Tuzcu EM, Hu T, Frid DJ, Nissen SE: Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J, 2006; 152: 1059-1063
21. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med, 2008; 359: 2417-2428
22. Jørgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol, 2000; 35: 592-599
23. Zanchetti A, Bond MG, Hennig M, Tang R, Hollweck R, Mancia G, Eckes L, Micheli D; ELSA Investigators: Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens, 2004; 22: 1201-1212
24. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158
25. Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, Bruschke AV: Evidence for a synergistic effect of calcium channel blockers with lipidlowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol, 1996; 16: 425-430
26. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol, 1997; 30: 569-575
27. Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K: Azelnidipine has anti-atherosclerotic effects independent of its blood pressurelowering actions in monkeys and mice. Atherosclerosis, 2008; 196: 172-179
28. Takayama M, Matsubara M, Arakawa E, Takada C, Ina Y, Hasegawa K, Yao K: Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits. Vascul Pharmacol, 2007; 46: 302-308
29. Cristofori P, Crivellente F, Campagnola M, Pasini AF, Garbin U, Rigoni A, Tosetti M, Turton J, Faustinelli I, Cominacini L: Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation. Int J Exp Pathol, 2004; 85: 105-114
30. Cristofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, Turton J: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens, 2000; 18: 1429-1436
31. Kyselovic J, Martinka P, Batova Z, Gazova A, Godfraind T: Calcium channel blocker inhibits Western-type dietevoked atherosclerosis development in ApoE-deficient mice. J Pharmacol Exp Ther, 2005; 315: 320-328
32. Willis AL, Nagel B, Churchill V, Whyte MrA, Smith DL, Mahmud I, Puppione DL: Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Atheroslcerosis, 1985; 5: 250-255
33. Henry PD, Bentley KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest, 1981; 68: 1366-1369
34. Atkinson JB, Swift LL: Nifedipine reduces atherogenesis in cholesterol-fed heterozygous WHHL rabbits. Atherosclerosis, 1990; 84: 195-201
35. Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa T, Araki E: Nifedipine induces peroxisome proliferator-activated receptor-γ activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2010; 30: 1598-1605
36. Yamashita T, Kawashima S, Ozaki M, Rikitake Y, Hirase T, Inoue N, Hirata K, Yokoyama M: A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens, 2001; 19: 451-458
37. Anacak GY, Ustünes L, Dilsiz OY, Ergul A: Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure. Vascul Pharmacol, 2010; 53: 193-199
38. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ: Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest, 1994; 94: 877-884
39. Sakamoto W, Fujie K, Handa H: Inhibition of prostaglandin E2 and superoxide anion production in rat peritoneal macrophages by the calcium antagonists nifedipine and nisoldipine. Arzneimittelforschung, 1991; 41: 781-785
40. Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol, 2006; 546: 11-18
41. Matsubara M, Hasegawa K: Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis, 2005; 178: 57-66
42. Berkels R, Breitenbach T, Bartels H, Taubert D, Rosenkranz A, Klaus W, Roesen R: Different antioxidative potencies of dihydropyridine calcium channel modulators in various models. Vascul Pharmacol, 2005; 42: 145-152
43. Toba H, Shimizu T, Miki S, Inoue R, Yoshimura A, Tsukamoto R, Sawai N, Kobara M, Nakata T: Calcium channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens Res, 2006; 29: 105-116
44. Yoshii T, Iwai M, Zhen Li Z, Chen R, Ide A, Fukunaga S, Oshita A, Mogi M, Higaki J, Masatsugu Horiuchi M: Regression of atherosclerosis by amlodipine via antiinflammatory and anti-oxidative stress actions. Hypertens Res, 2006; 29: 457-466
45. Wang N, Minatoguchi S, Chen XH, Arai M, Uno Y, Lu C, Misao Y, Nagai H, Takemura G, Fujiwara H: Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase C-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol, 2004; 43: 747-757
46. Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, Asayama J, Kobara M, Nakata T: Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res, 2005; 28: 689-700
47. Brovkovych V, Kalinowski L, Muller-Peddinghaus R, Malinski T: Synergistic Antihypertensive Effects of Nifedipine on Endothelium: Concurrent Release of NO and Scavenging of Superoxide. Hypertension, 2001; 37: 34-39
48. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol, 1999; 31: 275-281
49. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, Salvetti A: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension, 2001; 37: 943-948
50. Rachmani R, Levi Z, Zadok BS, Ravid M: Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther, 2002; 72: 302-307
51. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet, 1994; 344: 793-795
52. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 1997; 272: 20963-20966
53. Mason RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis, 2002; 165: 191-199
54. Kramsch DM, Sharma RC: Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens, 1995; 9(suppl 1): S3-S9
55. Chen L, Haught WH, Yang B, Saldeen TGP, Parthasarathy S, Mehta JL: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol, 1997; 30: 569-575
56. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol, 1999; 31: 275-281
57. Libby P: Inflammation in atherosclerosis. Nature, 2002; 420: 868-874
58. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its antioxidative properties. J Cardiovasc Pharmacol, 2004; 43: 724-730
59. Matsui T, Yamagishi S, Nakamura K, Inoue H: Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res, 2006; 34: 671-675
60. Costa S, Zimetti F, Pedrelli M, Cremonesi G, Bernini F: Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res, 2010; 62: 265-270
61. Yamagishi S, Inagaki Y, Kikuchi S: Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res, 2003; 29: 147-152
62. Wu L, Iwai M, Li Z, Li JM, Mogi M, Horiuchi M: Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor κB kinase and nuclear factor κBinducing kinase. J Hypertens, 2006; 24: 123-130
63. Matsubara M, HasegawaK: Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur J Pharmacol, 2004; 498: 303-314
64. Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T: Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol, 2006; 546: 11-18
65. Takahashi K, Shimokado K, Yoshida M: SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition. Eur J Pharmacol, 2006; 552: 162-169
66. Cominacini L, Pasini AF, Pastorino AM, Garbin U, Davoli A, Rigoni A, Campagnola M, Tosetti ML, Rossato P, Gaviraghi G: Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-α on endothelial cells. J Hypertens, 1999; 17: 1837-1841
67. Cominacini L, Garbin U, Fratta Pasini A, Paulon T, Davoli A, Campagnola M, Marchi E, Pastorino AM, Gaviraghi G, Lo Cascio V: Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxi dant signals on endothelial cells. J Hypertens, 1997; 15: 1633-1640
68. Li Q, Verma IM: NF-κB regulation in the immune system. Nat Rev Immunol, 2002; 2: 725-734
69. Agrawal A, Cha-Molstad H, Samols D, Kushner I: Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein beta (C/EBPβ) and Rel p50. J Immunol, 2001; 166: 2378-2384
70. Ferran C, Millan MT, Csizmadia V, Cooper JT, Brostjan C, Bach FH, Winkler H: Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Commun, 1995; 214: 212-223
71. Wang T, Zhang X, Li JJ: The role of NF-κB in the regulation of cell stress responses. Int Immunopharmacol, 2002; 2: 1509-1520
72. Vlahopoulos S, Boldogh I, Casola A, Brasier AR: Nuclear factor-κB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood, 1999; 94: 1878-1889
73. Matsumori A, Nunokawa Y, Sasayama S: Nifedipine inhibits activation of transcription factor NF-κB. Life Sci, 2000; 67: 2655-2661
74. Hayashi M, Yamaji Y, Nakazato Y, Saruta T: The effects of calcium channel blockers on nuclear factor κB activation in the mesangium cells. Hypertens Res, 2000; 23: 521-525
75. Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Oiso Y, Nakashima N: Nilvadipine inhibits nuclear factor-κB-dependent transcription in hepatic cells. Clinica Chimica Acta, 2004; 350: 151-157
76. Szabó C, Thiemermann C, Vane JR: Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Biochem Biophys Res Commun, 1993; 196: 825-830
77. Hattori Y, Kasai K, So S, Hattori S, Banba N, Shimoda S: Effects of calcium channel antagonists on the induction of nitric oxide synthase in cultured cells by immunostimulants. Life Sci, 1995; 57: 1833-1840
78. Takayama M, Yao K, Wada M: The dihydropyridine calcium channel blocker benidipine prevents lysophosphatidylcholine-induced endothelial dysfunction in rat aorta. J Biomed Sci, 2009; 16: 57-66
79. Sugano M, Tsuchida K, Makino N: Nifedipine prevents apoptosis of endothelial cells induced by oxidized lowdensity lipoproteins. J Cardiovasc Pharmacol, 2002; 40: 146-152
80. Ando H, Nakanishi K, Shibata M, Hasegawa K, Yao K, Miyaji H: Benidipine, a dihydropyridine-Ca2+ channel blocker, increases the endothelial differentiation of endothelial progenitor cells in vitro. Hypertens Res, 2006; 29: 1047-1054
81. Lusis AJ: Atherosclerosis. Nature, 2000; 407: 233-241
82. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993; 362: 801-809
83. Arakawa E, Hasegawa K: Benidipine, a calcium channel blocker, regulates proliferation and phenotype of vascular smooth muscle cells. J Pharmacol Sci, 2006; 100: 149-156
84. Corsini A, Bonfatti M, Quarato P, Accomazzo MR, Raiteri M, Sartani A, Testa R, Nicosia S, Paoletti R, Fumagalli R: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol, 1996; 28: 687-694
85. Absher MP, Baldor L, Warshaw DM: Effects of nitrendipine on growth activity in cultured vascular smooth muscle cells. J Cardiovasc Pharmacol, 1988; 12 Suppl 4: S104-S106
86. Ko Y, Totzke G, Graack GH, Heidgen FJ, Meyer zu Brickwedde MK, Düsing R, Vetter H, Sachinidis A: Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J Hypertens, 1993; 11: 1171-1178
87. Hirata Y, Eguchi S, Tsujino M: Effects of manidipine on DNA and protein syntheses in cultured vascular smooth muscle and endothelial cells and on proto-oncogene expression. Blood Press Suppl, 1992; 3: 30-35
88. Ide S, Kondoh M, Satoh H, Karasawa A: Anti-proliferative effects of benidipine hydrochloride in porcine cultured vascular smooth muscle cells and in rats subjected to balloon catheter-induced endothelial denudation. Biol Pharm Bull, 1994; 17: 627-631
89. Bernini F, Corsini A, Raiteri M, Soma MR, Paoletti R: Effects of lacidipine on experimental models of atherosclerosis. J Hypertens Suppl, 1993; 11: S61-S66
90. Hu WY, Fukuda N, Su JZ, Kanmatsuse K: Effects of the L-and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol, 2001; 38: 450-459
91. Tsukada T, Rosenfeld M, Ross R, Gown AM: Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis, 1986; 6: 601-613
92. Schwartz SM, Campbell GR, Campbell JH: Replication of smooth muscle cells in vascular disease. Circ Res, 1986; 58: 427-444
93. Canavesi M, Baldini N, Leonardi A, Sironi G, Bellosta S, Bernini F: In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol, 2004; 44: 416-422
94. Dushkin MI, Schwartz YS: Effect of verapamil and nifedipine on cholesteryl ester metabolism and low-density lipoprotein oxidation in macrophages. Biochem Pharmacol, 1995; 49: 389-397
95. Bernini F, Bellosta S, Didoni G, Fumagalli R: Calcium antagonists and cholesteryl ester metabolism in macrophages. J Cardiovasc Pharmacol, 1991; 18: S42-S45
96. Bernini F, Canavesi M, Bernardini E, Scurati N, Bellosta S, Fumagalli R: Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies. Br J Pharmacol, 1997; 122: 1209-1215
97. Etingin OR, Hajjar DP: Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect. J Clin Invest, 1985; 75: 1554-1558
98. Etingin OR, Hajjar DP: Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circ Res, 1990; 66: 185-190
99. Hasegawa K, Wakino S, Kanda T, Yoshioka K, Tatematsu S, Homma K, Takamatsu I, Sugano N, Hayashi K: Divergent action of calcium channel blockers on ATPbinding cassette protein expression. J Cardiovasc Pharmacol, 2005; 46: 787-793
100. Suzuki S, Nishimaki-Mogami T, Tamehiro N, Tamehiro M, Inoue K, Arakawa R, Abe-Dohmae S, Tanaka AR, Ueda K, Yokoyama S: Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol, 2004; 24: 519-525
101. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest, 1999; 104: R25-R31
102. Dollery CM, Mcewan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res, 1995; 77: 863-868
103. Bellosta S, Canavesi M, Favari E, Cominacini L, Gaviraghi G, Fumagalli R, Paoletti R, Bernini F: Lacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. J Pharmacol Exp Ther, 2001; 296: 736-743
104. Ikeda U, Hojo Y, Ueno S, Arakawa H, Shimada K: Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J Cardiovasc Pharmacol, 2000; 35: 887-890
105. Roth M, Eickelberg O, Kohler E, Erne P, Block LH: Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A, 1996; 93: 5478-5482
106. Anacak GY, Ustünes L, Dilsiz OY, Ergul A: Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure. Vascul Pharmacol, 2010; 53: 193-199
107. Spiegelman BM: Peroxisome proliferator-activated receptor γ: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res, 1997; 2: 457-464
108. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell, 1995; 83: 813-819
109. Ricote M Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998; 391: 79-82
110. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B: Peroxisome proliferator-activated receptor activators inhibit thrombininduced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res, 1999; 85: 394-402
111. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res, 1998; 83: 1097-1103
112. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophage in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol, 1998; 153: 17-23
113. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK: Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A, 1998; 95: 7614-7619
114. Francis GA, Annicotte JS, Auwerx J: PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol, 2003; 3: 186-191
115. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest, 2000; 106: 523-531
116. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest, 2004; 114: 1564-1576
117. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol, 2001; 21: 372-377
118. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2001; 21: 365-371
119. Claudel T, Leibowitz MD, Fievet C Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A, 2001; 98: 2610-2615
120. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet, 2005; 366: 1279-289
121. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 2006; 296: 2572-2581
122. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA, 2008; 299: 1561-1573
123. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K: Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J, 2009; 73: 343-351
124. Hashimoto R, Umemoto S, Guo F, Umeji K, Itoh S, Kishi H, Kobayashi S, Matsuzaki M: Nifedipine activates PPARγ and exerts antioxidative action through Cu/ZnSOD independent of blood-pressure lowering in SHRSP. J Atheroscler Thromb, 2010; 17: 785-795
125. Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S: Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-γ activation. Biochem Biophys Res Commun, 2009; 385: 269-272
126. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M: Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. Hypertension, 2008; 51: 528-533
127. Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M: Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther, 2006; 319: 1081-1087
128. Kosegawa I, Inaba M, Morita T, Awata T, Katayama S: Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens, 1998; 20: 751-761